Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity

Cancer Biomarkers Defined by Autoantibody Signatures to Aberrant O-Glycopeptide Epitopes

(2010) H. H. Wandall et al.   CANCER RESEARCH

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro

(2010) N. Geis et al.   CURRENT CANCER DRUG TARGETS

Expression of aberrantly glycosylated Mucin-1 in ovarian cancer

(2010) Catharina H M J Van Elssen et al.   HISTOPATHOLOGY

MUC1 immunotherapy

(2010) Richard E Beatson et al.   Immunotherapy

Seromic profiling of colorectal cancer patients with novel glycopeptide microarray

(2010) Johannes W. Pedersen et al.   INTERNATIONAL JOURNAL OF CANCER

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

Random Glycopeptide Bead Libraries for Seromic Biomarker Discovery

(2010) Stjepan K. Kračun et al.   JOURNAL OF PROTEOME RESEARCH

Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas

(2010) Xiao-Na Fan et al.   PATHOLOGY RESEARCH AND PRACTICE

The genetic and evolutionary balances in human NK cell receptor diversity

(2008) Peter Parham   SEMINARS IN IMMUNOLOGY

Mucin-type O-glycosylation and its potential use in drug and vaccine development

(2007) Mads Agervig Tarp et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS